Evaluation of a 68Ga-Labeled DOTA-Tetrazine as a PET Alternative to 111In-SPECT Pretargeted Imaging

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Evaluation of a 68Ga-Labeled DOTA-Tetrazine as a PET Alternative to 111In-SPECT Pretargeted Imaging. / Edem, Patricia E.; Jorgensen, Jesper T.; Norregaard, Kamilla; Rossin, Rafaella; Yazdani, Abdolreza; Valliant, John F.; Robillard, Marc; Herth, Matthias M.; Kjaer, Andreas.

I: Molecules, Bind 25, Nr. 3, 463, 2020.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Edem, PE, Jorgensen, JT, Norregaard, K, Rossin, R, Yazdani, A, Valliant, JF, Robillard, M, Herth, MM & Kjaer, A 2020, 'Evaluation of a 68Ga-Labeled DOTA-Tetrazine as a PET Alternative to 111In-SPECT Pretargeted Imaging', Molecules, bind 25, nr. 3, 463. https://doi.org/10.3390/molecules25030463

APA

Edem, P. E., Jorgensen, J. T., Norregaard, K., Rossin, R., Yazdani, A., Valliant, J. F., Robillard, M., Herth, M. M., & Kjaer, A. (2020). Evaluation of a 68Ga-Labeled DOTA-Tetrazine as a PET Alternative to 111In-SPECT Pretargeted Imaging. Molecules, 25(3), [463]. https://doi.org/10.3390/molecules25030463

Vancouver

Edem PE, Jorgensen JT, Norregaard K, Rossin R, Yazdani A, Valliant JF o.a. Evaluation of a 68Ga-Labeled DOTA-Tetrazine as a PET Alternative to 111In-SPECT Pretargeted Imaging. Molecules. 2020;25(3). 463. https://doi.org/10.3390/molecules25030463

Author

Edem, Patricia E. ; Jorgensen, Jesper T. ; Norregaard, Kamilla ; Rossin, Rafaella ; Yazdani, Abdolreza ; Valliant, John F. ; Robillard, Marc ; Herth, Matthias M. ; Kjaer, Andreas. / Evaluation of a 68Ga-Labeled DOTA-Tetrazine as a PET Alternative to 111In-SPECT Pretargeted Imaging. I: Molecules. 2020 ; Bind 25, Nr. 3.

Bibtex

@article{313f38a0779a4b2c8401a7bd1d5c8be4,
title = "Evaluation of a 68Ga-Labeled DOTA-Tetrazine as a PET Alternative to 111In-SPECT Pretargeted Imaging",
abstract = "The bioorthogonal reaction between a tetrazine and strained trans-cyclooctene (TCO) has garnered success in pretargeted imaging. This reaction was first validated in nuclear imaging using an In-111-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-linked bispyridyl tetrazine (Tz) ([In-111]In-DOTA-PEG(11)-Tz) and a TCO functionalized CC49 antibody. Given the initial success of this Tz, it has been paired with TCO functionalized small molecules, diabodies, and affibodies for in vivo pretargeted studies. Furthermore, the single photon emission tomography (SPECT) radionuclide, In-111, has been replaced with the beta-emitter, Lu-177 and alpha-emitter, Pb-212, both yielding the opportunity for targeted radiotherapy. Despite use of the 'universal chelator', DOTA, there is yet to be an analogue suitable for positron emission tomography (PET) using a widely available radionuclide. Here, a Ga-68-labeled variant ([Ga-68]Ga-DOTA-PEG(11)-Tz) was developed and evaluated using two different in vivo pretargeting systems (Aln-TCO and TCO-CC49). Small animal imaging and ex vivo biodistribution studies were performed and revealed target specific uptake of [Ga-68]Ga-DOTA-PEG(11)-Tz in the bone (3.7 %ID/g, knee) in mice pretreated with Aln-TCO and tumor specific uptake (5.8 %ID/g) with TCO-CC49 in mice bearing LS174 xenografts. Given the results of this study, [Ga-68]Ga-DOTA-PEG(11)-Tz can serve as an alternative to [In-111]In-DOTA-PEG(11)-Tz.",
keywords = "tetrazine ligation, PET, SPECT, gallium-68, indium-11",
author = "Edem, {Patricia E.} and Jorgensen, {Jesper T.} and Kamilla Norregaard and Rafaella Rossin and Abdolreza Yazdani and Valliant, {John F.} and Marc Robillard and Herth, {Matthias M.} and Andreas Kjaer",
year = "2020",
doi = "10.3390/molecules25030463",
language = "English",
volume = "25",
journal = "Molecules",
issn = "1420-3049",
publisher = "M D P I AG",
number = "3",

}

RIS

TY - JOUR

T1 - Evaluation of a 68Ga-Labeled DOTA-Tetrazine as a PET Alternative to 111In-SPECT Pretargeted Imaging

AU - Edem, Patricia E.

AU - Jorgensen, Jesper T.

AU - Norregaard, Kamilla

AU - Rossin, Rafaella

AU - Yazdani, Abdolreza

AU - Valliant, John F.

AU - Robillard, Marc

AU - Herth, Matthias M.

AU - Kjaer, Andreas

PY - 2020

Y1 - 2020

N2 - The bioorthogonal reaction between a tetrazine and strained trans-cyclooctene (TCO) has garnered success in pretargeted imaging. This reaction was first validated in nuclear imaging using an In-111-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-linked bispyridyl tetrazine (Tz) ([In-111]In-DOTA-PEG(11)-Tz) and a TCO functionalized CC49 antibody. Given the initial success of this Tz, it has been paired with TCO functionalized small molecules, diabodies, and affibodies for in vivo pretargeted studies. Furthermore, the single photon emission tomography (SPECT) radionuclide, In-111, has been replaced with the beta-emitter, Lu-177 and alpha-emitter, Pb-212, both yielding the opportunity for targeted radiotherapy. Despite use of the 'universal chelator', DOTA, there is yet to be an analogue suitable for positron emission tomography (PET) using a widely available radionuclide. Here, a Ga-68-labeled variant ([Ga-68]Ga-DOTA-PEG(11)-Tz) was developed and evaluated using two different in vivo pretargeting systems (Aln-TCO and TCO-CC49). Small animal imaging and ex vivo biodistribution studies were performed and revealed target specific uptake of [Ga-68]Ga-DOTA-PEG(11)-Tz in the bone (3.7 %ID/g, knee) in mice pretreated with Aln-TCO and tumor specific uptake (5.8 %ID/g) with TCO-CC49 in mice bearing LS174 xenografts. Given the results of this study, [Ga-68]Ga-DOTA-PEG(11)-Tz can serve as an alternative to [In-111]In-DOTA-PEG(11)-Tz.

AB - The bioorthogonal reaction between a tetrazine and strained trans-cyclooctene (TCO) has garnered success in pretargeted imaging. This reaction was first validated in nuclear imaging using an In-111-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-linked bispyridyl tetrazine (Tz) ([In-111]In-DOTA-PEG(11)-Tz) and a TCO functionalized CC49 antibody. Given the initial success of this Tz, it has been paired with TCO functionalized small molecules, diabodies, and affibodies for in vivo pretargeted studies. Furthermore, the single photon emission tomography (SPECT) radionuclide, In-111, has been replaced with the beta-emitter, Lu-177 and alpha-emitter, Pb-212, both yielding the opportunity for targeted radiotherapy. Despite use of the 'universal chelator', DOTA, there is yet to be an analogue suitable for positron emission tomography (PET) using a widely available radionuclide. Here, a Ga-68-labeled variant ([Ga-68]Ga-DOTA-PEG(11)-Tz) was developed and evaluated using two different in vivo pretargeting systems (Aln-TCO and TCO-CC49). Small animal imaging and ex vivo biodistribution studies were performed and revealed target specific uptake of [Ga-68]Ga-DOTA-PEG(11)-Tz in the bone (3.7 %ID/g, knee) in mice pretreated with Aln-TCO and tumor specific uptake (5.8 %ID/g) with TCO-CC49 in mice bearing LS174 xenografts. Given the results of this study, [Ga-68]Ga-DOTA-PEG(11)-Tz can serve as an alternative to [In-111]In-DOTA-PEG(11)-Tz.

KW - tetrazine ligation

KW - PET

KW - SPECT

KW - gallium-68

KW - indium-11

U2 - 10.3390/molecules25030463

DO - 10.3390/molecules25030463

M3 - Journal article

C2 - 31979070

VL - 25

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 3

M1 - 463

ER -

ID: 237651542